Welcome to our dedicated page for Hercules Capital news (Ticker: HTGC), a resource for investors and traders seeking the latest updates and insights on Hercules Capital stock.
Hercules Capital, Inc. (NYSE: HTGC) is a premier specialty finance company dedicated to providing senior secured loans to high-growth, venture capital-backed companies in technology-related markets. Established in December 2003, Hercules has positioned itself as a key player in the venture lending space, committing over $4.6 billion to more than 300 companies across various stages of development. The company focuses on sectors such as technology, biotechnology, life sciences, and sustainable and renewable energy.
Hercules Capital stands out by offering more than just financial support. The company provides vital access to its expansive network of contacts and invaluable business advice, helping entrepreneurial companies achieve significant milestones. Their investment portfolio includes a mix of structured debt with warrants, senior debt, and equity investments.
Recent achievements include a $35 million loan facility to SynOx Therapeutics Limited to support the development of emactuzumab, a next-generation monoclonal antibody for treating Tenosynovial Giant Cell Tumour (TGCT). Another notable investment is the $150 million financing to Harness, a Modern Software Delivery Platform company, to expand its platform with new modules and enhance its use of generative AI.
Hercules Capital’s strategic partnerships and financial solutions make it the lender of choice for venture-backed companies seeking reliable growth capital. The company’s financial stability and extensive industry expertise ensure that it remains a trusted partner for innovation-driven businesses looking to scale.
Hercules Capital, Inc. (NYSE: HTGC) has announced the participation of its executive management team in several upcoming financial community events. These include the Jefferies BDC Summit and FitchRatings BDC Conference on November 16, 2022, followed by the JMP Securities Financial Services and Real Estate Conference on November 17, 2022. Hercules Capital, the largest specialty financing provider, has committed over $16 billion to more than 600 companies since its inception in December 2003, focusing on senior secured venture growth loans for innovative sectors.
Hercules Capital, Inc. (NYSE: HTGC) reported a record total gross debt and equity commitments of
Undistributed earnings stand at
Bright Machines has secured
Tricida, Inc. (NASDAQ: TCDA) announced a $125 million debt facility with Hercules Capital, Inc. (NYSE: HTGC). Of this, $100 million is available for Tricida upon meeting certain milestones. This financing aims to support the upcoming NDA resubmission and FDA approval for their drug, veverimer, designed to treat chronic kidney disease (CKD). The loan allows for interest-only payments until August 2024, with possible extensions based on FDA decisions. This partnership is intended to provide non-dilutive capital for Tricida's ongoing development of veverimer.
Hercules Capital, Inc. (NYSE: HTGC) has scheduled its third quarter 2022 financial results conference call for November 2, 2022, at 2:00 p.m. PT (5:00 p.m. ET). Financial results will be released after market close on the same day. The company is a leader in providing senior secured venture growth loans, having committed over $15 billion to more than 590 companies since its inception in December 2003. Investors can access a live webcast of the call on their website, with an archived version available for 30 days.
Hercules Capital, Inc. (NYSE: HTGC) has announced a supplemental cash distribution of
Hercules Capital (NYSE: HTGC) has declared a third-quarter 2022 cash distribution of $0.36 per share, with key dates of record on November 10, 2022 and payment on November 17, 2022. The company follows a variable distribution policy, aiming to distribute up to 100% of its taxable income for the year. For Q3 2022, 100% of the declared distributions were from current earnings. Additionally, 87.1% of these distributions qualify as “Qualified Interest Income” exempt from U.S. withholding tax for foreign shareholders.
Hercules Capital, Inc. (NYSE: HTGC) announced that Kroll Bond Rating Agency reaffirmed its investment grade corporate and credit rating at BBB+ with a stable outlook. This rating underscores Hercules' effective venture capital lending strategy and the strong management team's capabilities. The rating reflects the company's focus on senior secured debt investments in technology and life sciences, minimal non-accruals, and solid capital market access. Since its inception, Hercules has committed over $15 billion to more than 590 companies, establishing itself as a leading finance provider.
Provention Bio (Nasdaq: PRVB) announced a term loan facility worth up to $125 million with Hercules Capital (NYSE: HTGC) to bolster its financial standing ahead of the potential commercial launch of teplizumab. The loan is structured in five tranches, with an initial draw of $25 million at closing and the possibility of further disbursements contingent on FDA approval and achievement of specific milestones. This financing aims to enhance the development of therapies for type 1 diabetes and improve the lives of affected individuals.
Hercules Capital (NYSE: HTGC) reported record financial metrics for the first half of 2022, including total gross debt and equity commitments of
FAQ
What is the current stock price of Hercules Capital (HTGC)?
What is the market cap of Hercules Capital (HTGC)?
What does Hercules Capital, Inc. specialize in?
Which industries does Hercules Capital, Inc. focus on?
How much has Hercules Capital, Inc. committed since its inception?
What kind of financial products does Hercules Capital, Inc. offer?
Can you provide an example of a recent investment by Hercules Capital, Inc.?
Why do companies choose Hercules Capital, Inc.?
How does Hercules Capital, Inc. support its portfolio companies beyond financial investment?
What is a notable recent achievement of Hercules Capital, Inc.?
How does Hercules Capital, Inc. ensure its financial stability?